Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Yingke Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Yingke Capital

Yingke Capital

Operating

Yingke Capital, a principal investment firm, specializes in pre-IPO investments in high-tech sectors, founded in 2010.

Location
Fuzhou, Jiangxi, CN
Founded
2010
Firm
Compare
Portfolio
Employees
Website

Yingke Capital is a principal investment firm founded in 2010 and headquartered in Fuzhou, China. The firm specializes in pre-IPO investments, focusing on sectors such as 5G internet of things, biomedical, environmental and facilities services, new energy, consumer upgrades, smart manufacturing, and materials. Yingke Capital typically invests in companies with strong technology R&D and production capabilities, participating in Series B, C, and D funding rounds.

Notable portfolio companies include Cloudbreak Therapeutics, Denovo Biopharma, Joinn Biologics, and Simcere Pharmaceutical, with significant total capital raised by each. The firm was founded by Mingfei Qian and emphasizes a high-tech investment philosophy. Yingke Capital offers unique value-add services to its portfolio companies, leveraging its deep industry expertise and extensive network to support growth and innovation.

Yingke Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments4
Current Portfolio Count4
Total Portfolio Exits0

Top Investment Stages

Series B2 (50.0%)
Series C1 (25.0%)
Series D1 (25.0%)

Stage Mix

Series B 50%Series C 25%Series D 25%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Cloudbreak Therapeutics logo

Cloudbreak Therapeutics

Joinn Biologics logo

Joinn Biologics

Simcere Pharmaceutical logo

Simcere Pharmaceutical

Denovo Biopharma logo

Denovo Biopharma

Yingke Capital - Similar Investment Firms

YF Capital logo

YF Capital

yfc.cn

Dyee Capital logo

Dyee Capital

dyeecapital.com

Yonghua Capital logo

Yonghua Capital

Kunlun Capital logo

Kunlun Capital

kunlun-cap.com

Yunshan Capital Partners logo

Yunshan Capital Partners

Xianghe Capital logo

Xianghe Capital

xianghecap.com

Kaitai Capital logo

Kaitai Capital

kaitaicapital.com

YuanMing Capital logo

YuanMing Capital

Fanchuang Capital logo

Fanchuang Capital

inventioncap.cn

Industrial Securities Capital logo

Industrial Securities Capital

capital.xyzq.cn

Fengshion Capital logo

Fengshion Capital

Pre-IPO Capital Partners logo

Pre-IPO Capital Partners

preipo.cn

Yuan Capital logo

Yuan Capital

Jinqiu Capital logo

Jinqiu Capital

jinqiucapital.com

Kaiwu Capital logo

Kaiwu Capital

Yingke Capital - Classification

Also Known As
  • Yingke Innovation Asset Management Co., Ltd.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 5 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
SIC
  • 6000Depository Institutions
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified